{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-001973","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2022-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.365729+00:00","generated_at":"2026-06-27T04:59:54.912187+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Relay Therapeutics reports FY2021 net loss of $363.9M; cash $958M into 2025","bullets":["Q4 net loss $67.5M vs net income $35.3M in Q4 2020; full-year net loss $363.9M ($3.82 loss per share).","Cash, cash equivalents and investments $958.1M at Dec 31 2021, expected to fund operations into at least 2025.","R&D expenses $172.7M for FY2021 (up from $99.9M in FY2020), driven by clinical trial and employee costs.","Announced interim data for RLY-4008 (FGFR2 inhibitor) showing tumor shrinkage in all six treatment-naïve FGFR2 fusion+ cholangiocarcinoma patients.","Dosed first patient in RLY-2608 (pan-mutant PI3Kα inhibitor) first-in-human trial; FDA granted orphan drug designation for RLY-4008 in cholangiocarcinoma."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-001973","json":"https://secwatch.observer/filing/0000950170-22-001973.json","markdown":"https://secwatch.observer/filing/0000950170-22-001973.md","text":"https://secwatch.observer/filing/0000950170-22-001973.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017022001973/0000950170-22-001973-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017022001973/rlay-20220224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T04:59:54.912187+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}